Shots: The study evaluates the effectiveness of the Guardant Reveal liquid biopsy test to detect MRD in patients with stage I-IV colorectal cancer after curative intent therapy The blood samples […]readmore
Tags : colorectal cancer
Shots: The company has launched Guardant Reveal liquid biopsy test for the detection of residual and recurrent disease from a simple blood draw to monitor CRC patients with 7-day turnaround […]readmore
Shots: The approval is based on pivotal P-III KEYNOTE-177 study involves assessing of Keytruda (200mg, q3w) vs CT regimen in 307 patients in a ratio (1:1) with previously untreated metastatic […]readmore
Shots: Boehringer Ingelheim (BI) and Amal Therapeutics enter into a clinical research agreement to conduct P-Ib KISIMA-01 study assessing Amal’s ATP128 and BI’s BI754091 with microsatellite stable (MSS) patients with […]readmore
Shots: Indivumed to receive upfront from Evotec, for accessing Indivumed’s database “IndivuType” and both companies will jointly invest in data analysis, target identification, validation, and drug discovery. Evotec will be […]readmore
Biosimilars
Biotech
Innovent Biologics Reports Acceptance of BLA for IBI-305 (bevacizumab, biosimilar)
Shots: The BLA is based on two P-III study results assessing efficacy, safety and PK of IBI-305 vs bevacizumab in patients with advanced non-sq NSCLC and has demonstrated in meeting […]readmore
Shots: The P-I THINK ongoing trial is assessing CYAD-01 in mCRC patients administering cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²), evaluating its safety and ATR CYAD-01 investigational CAR-T therapy with […]readmore